Lizzy Smyth: Radiotherapy does not add to mFOLFIRINOX in borderline resectable Pancreatic Cancer

Lizzy Smyth, Consultant Medical Oncologist in upper GI oncology at Oxford University NHS Foundation Trust, shared a post on X:

“Radiotherapy does not add to mFOLFIRINOX in borderline resectable Pancreatic Cancer – results for PRODIGE-44.

Good news for patients with PDAC – mFOLFIRINOX had outcomes (mOS 32.8m, 47.9m OS if resected).

Results confirm ESMO guidelines recommendations.”

Sunnie Kim, GI Medical Oncologist at University of Colorado Cancer Center, shared this post, adding:

“Pancreatic cancer is a systemic disease unless proven otherwise!”

Sources: Lizzy Smyth/X and Sunnie Kim/X